Navigation Links
BioSpecifics Technologies Corp. Reports Third Quarter 2012 Financial Results
Date:11/8/2012

LYNBROOK, N.Y., Nov. 8, 2012 /PRNewswire/ -- BioSpecifics Technologies Corp. (NASDAQ: BSTC), a biopharmaceutical company developing first in class collagenase-based products marketed as XIAFLEX® in the U.S. and XIAPEX® in Europe and Eurasia, today announced its financial results for the third quarter ended September 30, 2012 and provided a corporate update.

"We are very happy with the ongoing clinical development progress for our XIAFLEX pipeline, including the recent submission of a sBLA filing by our partner Auxilium for the potential treatment of Peyronie's disease," said Thomas L. Wegman, President of BioSpecifics. "Additionally, Auxilium recently completed enrollment in its cellulite Phase Ib and frozen shoulder Phase IIa studies and began enrollment for its 600 patient label expansion study for Dupuytren's contracture patients with multiple palpable cords. We look forward to reporting top-line data from each of these studies in the fourth quarter of 2012, the first quarter of 2013 and the first half of 2014, respectively. We also anticipate that we will complete enrollment in our internally-managed human and canine lipoma Phase II trials during the first half of 2013. In addition, we are very encouraged by the ongoing commercial initiatives Auxilium has implemented to continue to expand XIAFLEX sales for Dupuytren's contracture in the U.S."

Third Quarter 2012 Financial Results
BioSpecifics reported net income of $0.5 million for the third quarter ended September 30, 2012, or $0.07 per basic and diluted common share, compared to a net income of $0.3 million, or $0.04 per basic and diluted common share, for the same period in 2011.

Total revenue for the third quarter of 2012 was $2.4 million, compared to $1.9 million for the same period in 2011.

Royalty, mark-up on cost of goods sold, and earn-out revenues for the third quart
'/>"/>

SOURCE BioSpecifics Technologies Corp.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. BioSpecifics Technologies Corp. To Present at UBS Global Life Sciences Conference
2. BioSpecifics Technologies Corp. Reports Second Quarter 2012 Financial Results
3. BioSpecifics Technologies Corp. Announces Presentations at Two Upcoming Investor Conferences in March
4. BioSpecifics Technologies Corp. Announces Appointment of George Gould to Board of Directors
5. Palatin Technologies Reports Positive Results for Phase 2B Bremelanotide Female Sexual Dysfunction Trial
6. Patient Safety Technologies Reports Third Quarter 2012 Results
7. Life Technologies Announces Third Quarter 2012 Results
8. Life Technologies Reschedules Issuance Of Third Quarter 2012 Performance Report And Associated Conference Call And Webcast to Thursday, November 1, 2012 Due To Expected Severe Weather Conditions
9. Life Technologies New State-of-the-Art Manufacturing Facility in China Provides Forensics Labs Rapid Access to World-Leading DNA Testing Solutions
10. $1 Million Global B.R.A.I.N. Prize Announced by Israel Brain Technologies
11. Palatin Technologies, Inc. Reports Fourth Quarter and Fiscal Year End 2012 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/3/2015)... Aug. 3, 2015   Intrexon Corporation (NYSE: ... half and second quarter 2015 financial results after the ... The Company will host a conference call at 5:30 ... general business update. The conference call may ... (International), and asking to join the "Intrexon Corporation Call."  ...
(Date:7/31/2015)... , ... July 31, 2015 , ... ... competitive market analysis and premium industry insights on the global resorcinol industry. The ... a collective study of vivid market scenarios and analysis of primary and secondary ...
(Date:7/30/2015)... 30, 2015   GenoSpace , a leading ... and analysis of genomic and other biomedical data, ... joined the company as Vice President of Sales ... "GenoSpace partners with its ... analyze and explore complex sets of genomic, phenotypic ...
(Date:7/30/2015)... 2015   Aratana Therapeutics, Inc . (NASDAQ: ... on the licensing, development and commercialization of innovative ... its strategic partner VetStem Biopharma, Inc. has shared ... AT-016, an adipose-derived allogeneic stem cell product exclusively ... pain in dogs. The double-blinded, multi-site, ...
Breaking Biology Technology:Intrexon to Announce First Half and Second Quarter 2015 Financial Results and Host Conference Call on August 10th 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 2Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 3Resorcinol Market to Grow at 6% CAGR to 2019 Says New Research Report at ReportsnReports.com 4GenoSpace Introduces Matthew Fischer as Vice President of Sales and Marketing 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 2Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 3Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 4Aratana Therapeutics Announces Positive Pilot Field Study for AT-016 5
... Call and Webcast on March 14 at 8:00 a.m. PDT ... ... March 13 Halozyme Therapeutics,Inc. (Nasdaq: HALO ), a biopharmaceutical company ... three months and year ended December 31, 2007., "Our achievements in ...
... 13 /PRNewswire-FirstCall/ - Angiotech Pharmaceuticals,Inc. (NASDAQ: ANPI ... entered into a,definitive licensing agreement with privately held ... to market and distribute the,Option(TM) inferior vena cava ... the body,s inferior vena cava to prevent pulmonary ...
... EMERYVILLE, Calif., March 13 Bionovo, Inc.,(Nasdaq: ... Butler, Ph.D., to,the company,s Board of Directors. Dr. ... companies, and in particular in,advancing cancer drug development ... to have George on board as we move ...
Cached Biology Technology:Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 2Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 3Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 4Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 5Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 6Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 7Halozyme Therapeutics Reports Fourth Quarter and Year End 2007 Financial Results 8Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 2Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 3Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 4Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 5Angiotech and Rex Medical announce exclusive licensing and distribution agreement for the "Option(TM)" inferior vena cava filter 6George Butler Joins Bionovo's Board of Directors 2George Butler Joins Bionovo's Board of Directors 3
(Date:7/31/2015)... , Chine, 31 juillet 2015 ... www.icg-10.org ) sera organisée par le BGI ... Shenzhen en Chine. ... Depuis son inauguration en 2006, l,ICG est devenue ... dans le domaine des « omiques » et c,est aussi ...
(Date:7/31/2015)... The 10 th International Conference on Genomics ... 22-25, 2015, in Shenzhen , ... 10 th anniversary this year. Since its inauguration in ... annual meetings in the ,omics, fields, and is one of ... ICG-10 focuses on recent breakthroughs and advances in ,omics, ...
(Date:7/23/2015)... (NASDAQ: AWRE ), a leading supplier of biometrics software ... ended June 30, 2015.  Revenue for the ... 33% compared to $6.8 million in the same quarter last ... $0.3 million, or $0.01 per diluted share, which compared to ... period a year ago.  Lower revenue and ...
Breaking Biology News(10 mins):La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 2La 10e International Conference on Genomics (ICG-10) doit s'ouvrir en octobre 3The 10th International Conference on Genomics (ICG-10) to Open in October 2Aware, Inc. Reports Second Quarter 2015 Financial Results 2Aware, Inc. Reports Second Quarter 2015 Financial Results 3Aware, Inc. Reports Second Quarter 2015 Financial Results 4Aware, Inc. Reports Second Quarter 2015 Financial Results 5Aware, Inc. Reports Second Quarter 2015 Financial Results 6
... 2002-2003 was short-lived, but a novel type of human coronavirus ... humans and bats alike, a fact that could make the ... to be published in in mBio , the online ... 11. The new coronavirus, called hCoV-EMC, is blamed for five ...
... change, deforestation and toxic waste, the assumption has been that ... from the University of California, Berkeley, suggests that such viewpoints ... need to be better stewards of the land are couched ... "sanctity" of Earth and our bodies. A UC Berkeley ...
... Auditory systems differ between sexes in sparrows depending ... found. The work adds to our knowledge of how ... humans, are able to change. Megan Gall, a ... peripheral auditory systems of male and female house sparrows, ...
Cached Biology News:New coronavirus has many potential hosts, could pass from animals to humans repeatedly 2New coronavirus has many potential hosts, could pass from animals to humans repeatedly 3Conservatives can be persuaded to care more about the environment 2Conservatives can be persuaded to care more about the environment 3Researcher finds gender differences in seasonal auditory changes 2
...
CQCS kit for etra KR 4i , (other units)....
... Magnetic Stirrers operate without any moving parts ... making VARIOMAG Magnetic Stirrers 100% wear-free and ... can be hermetically sealed, making it inaccessible ... why VARIOMAG Magnetic Stirrers are particularly suitable ...
... Fluoroskan Ascent FL is ... and luminometric measurement technologies ... list of advanced features ... Luminoskan Ascent. Fluoroskan Ascent ...
Biology Products: